Member Directory

CFGI is an international, non-audit, accounting advisory firm free of auditor independence restrictions. Consisting of ex-Big4 professionals, CFGI is strategically positioned to help companies and private equity sponsors through a range of routine and complex business scenarios.

Founded in the US in 2000, and now operating across the UK, CFGI is ideally placed to support companies throughout their lifecycle, from ambitious high growth pre-revenue start-ups, right through to established, commercial public companies. CFGI has expertise across a wide range of sectors, with a particular specialism in Lifesciences and Healthcare.

Operating as a hands-on extension of your finance team, CFGI works alongside your people, serving in a variety of roles – from technical accounting advisor to M&A support, to IPO readiness to listed company financial reporting – and delivering seamless support services. Without the independence restrictions of an audit practice, CFGI’s model allows for a rapid, flexible and cost competitive response to deliver a tailored solution for each challenge encountered.

The range of areas of support include:
» Technical accounting
» IPO readiness and support
» Interim management
» Valuation
» Audit assistance
» Cybersecurity
» Risk advisory and controls
» Transaction services
» ESG implementation
» Financial reporting

www.cfgi.com

Contact Paul Cooper pcooper@cfgi.com

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Charles River Discovery

Discovery from Charles River is industry-proven in the successful development of novel therapies, with over 420 patents and 85 preclinical drug candidates delivered to our clients. Backed by more than 750 scientists, our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, pharmacology and toxicology services that support clients from the earliest stages of target discovery through IND. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market. To learn more, visit www.criver.com/products-services/discovery-services or to be part of our journey please explore our careers.

Chesterford Research Park offers advanced laboratory and office space set within 250 acres of idyllic parkland near Cambridge – modern, dynamic, flexible facilities perfectly appointed for biotechnology, pharmaceutical and technology R&D companies of all sizes. The Park is being developed as a 250 acre low density scheme, which means that the natural environment, arboretum and wide-open spaces play a crucial role alongside the cutting-edge research facilities. Not only that, but the purpose-built hub building, The Nucleus, at the heart of the Park provides all the facilities required to make working life simple, enjoyable and rewarding - as well as fostering collaboration between the community as they meet and interact there. Home to companies that are making a real difference, scientists, investors and entrepreneurs work side by side at Chesterford Research Park, developing life-changing drugs within a sustainable environment.

Previously known as Trinity Pharmaceuticals and acquired by the Italian company, Chiesi Farmaceutici S.p.A in 1999, Chiesi Ltd. is proud of its entrepreneurial heritage. Established in 1995, the then Huddersfield-based Trinity Pharmaceuticals specialised in cardiology, musculoskeletal and respiratory medicines. A modest sized company with real ambition, Trinity’s core objective was to satisfy patient needs whilst meeting those of the NHS.
Chiesi Limited embraces a shared set of corporate values that shape our day-to-day business practices and encourages cooperation with our employees and partners:

We have always adhered to a series of values in the pursuit of our company objectives, applying them on a daily basis in the work which we carry out and in our relationships with employees and partners:

Reliable company

We want to be recognised by all our stakeholders as a Company that adopts and promotes transparent ethical behaviour at all levels, in line with the norms and regulations that are inspired by Corporate Social Responsibility principles.

Chiesi is the largest global pharmaceutical group to be awarded B Corp Certification, a recognition of high social and environmental standards. It’s an achievement to be proud of, and yet it feels natural: caring for others is at the root of health science and it has always been at the core of our work.

Chiesi Ltd is the largest affiliate of the whole Chiesi Group, benefiting from over 20 years of continued year on year growth. In 2018, the UK generated revenues in excess of £250m and employs over 300 people across all business areas.

Our success results from combining an entrepreneurial spirit, operational excellence and a strong ambition for continued growth.

Chiesi has developed a deep understanding of the UK market and possesses expertise in the areas of regulatory approval, reimbursement and the commercialisation of pharmaceutical products across primary, specialised and orphan drug environments.

Our diverse range of products are supported by a large sales force, who are highly experienced at selling into primary, secondary and tertiary care within the NHS.In order to support Chiesi Limited’s ambitious growth plans, we are seeking product opportunities and commercial partnerships to complement and expand our current sales activities in the UK.

We endeavour to be a partner of choice by remaining flexible with regards to deal type and structure, seeking commercial arrangements which maximize the potential of every opportunity for all parties.

We are particularly interested in securing rights to on market products which align to our current portfolio in:
•Respiratory
•Neonatology
•Rare Diseases
•Transplantation

Additionally, we are also keen to hear about any other on or near market opportunities that have a focus on speciality care within the NHS which will complement our current business within the UK market.

A clear synergy existed between the two organisations making this a very successful combination.

CIMYM BioSciences is a healthcare company that uses its expertise to manage and perform value-enhancing activities in the development process of pharmaceuticals and diagnostics, including the design and conduct of clinical trials, the maintenance of intellectual property rights, interaction with investors and drug regulatory authorities internationally, and the securing of partners to assist in the development and commercialization processes. . . CIMYM principally co-develops and/or licenses the rights to manufacture or market these products to other pharmaceutical companies in exchange for license fees and royalty payments

CK Clinical is part of a family of science-based consultancies – The CK Group. We provide Functional Service Outsourcing services as well as helping to recruit for contract and permanent job opportunities across the UK and Europe. We aim to provide resource solutions that are tailored and cost effective to organisations ranging from small start ups to large international pharmaceutical companies. We have a track record delivering Functional Service outsourcing and contingency recruitment solutions to some of the most innovative new Biotechs right the way through to helping 9 of the top 10 major Pharma companies.

CMS is a full service law firm with a network of offices across Europe and beyond. We are leaders in the life sciences sector and have a strong track record of working with early-stage spin-outs through to major global companies. The sector presents its own unique challenges and needs. We have a team focused on building relationships and expertise required to deliver relevant advice. Our clients benefit from commercial no-nonsense advice, whether they are longstanding clients or prospective clients needing a second opinion or advice where others are conflicted. Our clients value our commercial advice, which is delivered at competitive prices.

CN Bio Innovations develops human organ-on-a-chip technologies: devices that enable the formation of miniature models of organs in the lab using living human cells. In 2016 we successsfully showcased the world's first 7-organ-on-a-chip platform. Over the past three years more than 25 pharmaceutical companies have used our devices to study the effects of drugs and other chemicals on organ function. CN Bio is also developing organ-on-a-chip models for specific diseases, including non-alcoholic steatohepatitis and hepatitis B. CN Bio is a co-recipient with MIT of a $26 million federal contract to develop next generation organs-on-chips and has also received InnovateUK grant awards.

Pages